Eric Schulze – CEO, Lifetrack Medical Systems
Lifetrack Medical Systems’ Dr Eric Schulze explores the origins of his company, how its software platform has the potential to revolutionise radiology workflows in Asia and beyond, and the barriers…
Address: 2 Chia Ping Road, # 09-01 Singapore 619968 ,Singapore
Tel: +65 6265 2777
Web: http://www.dha.asia/
Drug Houses of Australia Pte Ltd. (DHA) is a subsidiary of Watson Pharmaceuticals, Inc., New Jersey, USA., and operates an extensive network of pharmaceutical business operations in Southeast Asia. Watson Pharmaceuticals, Inc. is a leading integrated generic pharmaceutical company grossing a revenue of USD4.6 billion in 2011, and currently has operations spread across the globe.
DHA has already become a household name, with a strong brand build upon premium products, manufactured at their own facilities in Singapore and at other global sites via contract manufacturing. They ensure consistent high quality and reliability in every single product, and their manufacturing sites include those approved by stringent requirements of regulatory authorities such as USFDA, TGA & MHRA
Generic Drugs
Lifetrack Medical Systems’ Dr Eric Schulze explores the origins of his company, how its software platform has the potential to revolutionise radiology workflows in Asia and beyond, and the barriers…
Industry veteran Marine Queniart-Stojanovic, a self-described “global citizen with a French passport,” currently serves as Sanofi’s GM for general medicines in Thailand, Malaysia, and Singapore. With Sanofi undergoing a significant…
Alan Goh of NDR Medical Technology, a pioneer in intelligent navigation and image processing for minimally invasive surgery, introduces the progress of the company to date, how its technology has…
Singapore is one of the healthiest countries in Asia with a life expectancy in excess of 82 years buttressed by one of the most robust healthcare apparatuses in the world.…
IQVIA Biotech JAPAC’s Dr Senthil Sockalingam outlines the evolving needs of the flood of early-stage drug discovery ventures in Asia, how biotechs in the region differ from their counterparts in…
Singapore recently outlined its latest Research, Innovation and Enterprise (RIE) 2025 plan, with plans to invest some USD 20 billion over the next 5 years. Here, three key stakeholders from…
Industry veteran Marine Queniart-Stojanovic outlines the significance of the Thailand-Malaysia-Singapore country grouping to Sanofi’s APAC operations; how the company’s global rationalisation and prioritisation push has been reflected at the country…
Professor Ashok Venkitaraman introduces his work in Singapore, coordinating and catalysing research on the causes of cancer in Asia, and translating this research to clinical impact through improved detection, treatment…
Erika Pagani, country manager for Pfizer Singapore, shares her journey with the company from Brazil to New York, Peru, Ecuador, and finally Singapore. She discusses why the island city-state is…
Beh Kian Teik of Singapore’s National Research Foundation (NRF) outlines the importance of the life sciences within the country’s innovation strategy and the role it has to play at a…
EY’s Abhay Bangi highlights the key trends across the ASEAN life sciences space, how the COVID-19 pandemic has accelerated them, and charts Singapore’s course towards becoming a world-class biotech investment…
Innovation is at the heart of healthcare transformation and the doors for a much-needed shift from provider- to patient-centric solutions have been opened. That is the idea behind HealthBeats™, a…
See our Cookie Privacy Policy Here